Primary antiphospholipid syndrome

This phase 2 trial tested whether the drug telitacicept can reduce levels of harmful antibodies in 20 people with antiphospholipid syndrome, a condition that raises the risk of blood clots. Participants received either telitacicept plus standard care or standard care alone for 48…